{"organizations": [], "uuid": "777077e0274219b9db18a9844e3ed69cebbf1bc5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/27/globe-newswire-apricus-biosciences-announces-proposed-public-offering.html", "country": "US", "domain_rank": 767, "title": "Apricus Biosciences Announces Proposed Public Offering", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T00:33:00.000+03:00", "replies_count": 0, "uuid": "777077e0274219b9db18a9844e3ed69cebbf1bc5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/27/globe-newswire-apricus-biosciences-announces-proposed-public-offering.html", "ord_in_thread": 0, "title": "Apricus Biosciences Announces Proposed Public Offering", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}, {"name": "park avenue", "sentiment": "none"}], "organizations": [{"name": "apricus biosciences, inc.", "sentiment": "neutral"}, {"name": "securities and exchange commission", "sentiment": "none"}, {"name": "sec", "sentiment": "none"}, {"name": "llc", "sentiment": "none"}, {"name": "h.c. wainwright & co.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of shares of common stock and warrants to purchase shares of common stock.\nH.C. Wainwright & Co. is acting as exclusive placement agent for the offering.\nThe Company intends to use the net proceeds from the offering for working capital and general corporate purposes.\nThe shares and warrants are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-221285), that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on December 7, 2017. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and may also be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3 rd Floor, New York, NY 10022, by calling (646) 975-6996 or emailing placements@hcwco.com .\nThis press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Apricus Biosciences, Inc.\nApricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan); and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.\nFor further information on Apricus, visit http://www.apricusbio.com .\nVitaros ™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros ® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa ™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.\nForward Looking Statements\nThis press release contains within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are . Such include, among other things: Apricus’ expectations on the completion, timing and size of the offering and the anticipated use of proceeds therefrom. Actual results could differ from those projected in any due to a variety of reasons that are outside the control of Apricus, including, but not limited to: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering; and other risks and uncertainties inherent in Apricus’ business, including those described in the Apricus’ periodic filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. These are made as of the date of this press release, and Apricus assumes no obligation to update the , or to update the reasons why actual results could differ from those projected in the . Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from Apricus.\nCONTACT: Matthew Beck mbeck@troutgroup.com Solebury Trout (646) 378-2933\nSource:Apricus Biosciences, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=7_lmaBb1QNVR-q5pR65kmbTduVxYDvDXtpWEFSpMYAVdC6r7_uNYXOMnxj6u-lo22cXvhCzCYjmq_ho2aTX9aQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/3a46aef3-dbb8-4d4a-9d21-9c2cb70d783a", "https://www.globenewswire.com/Tracker?data=xxzbAJmZxvh1Krbufn0BB1-it_IM6phy67YXFcxIuHh2x91xYz8gQccY4CchIgGKhS_xT_e8bSYJM4VJqEtBzRkcnYv-er1fnB83mvCXMLM="], "published": "2018-03-28T00:33:00.000+03:00", "crawled": "2018-03-28T03:48:25.020+03:00", "highlightTitle": ""}